INOVIQ
LIVE

Serial Number

79349962

Owner

INOVIQ Limited

Attorney

Charles G. Zug

Filing Date

May 20, 2022

Add to watchlist:

No watchlists yet
View on USPTO

INOVIQ Trademark

Serial Number: 79349962 • Registration: 7601786

INOVIQ is a trademark filed by INOVIQ Limited on May 20, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

INOVIQ Limited (2 trademarks)

23 Normanby Road

Entity Type: 99

Trademark Details

Filing Date

May 20, 2022

Registration Date

December 17, 2024

Published for Opposition

October 15, 2024

Goods & Services

Scientific research, clinical research, development, advisory and consultancy services in relation to antibody production; vaccine screening, in the nature of research and development of vaccines; advisory services relating to diagnostic products for scientific research; advisory services relating to diagnostic products for scientific research, namely development of diagnostic products for scientific research, extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; computer-aided diagnostic testing services for others for scientific research purposes; scientific research for medical purposes; scientific research for medical purposes, namely, research services relating to diagnostic products for scientific research, extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; research services in the field of diagnostic preparations; preparation of reports relating to medical, scientific and technical research; provision of information relating to medical, scientific and technical research; research and development of products; research and development of products in the field of antibody generation; research and development of products, namely, new therapeutic products in the field of gene therapeutics and cell therapeutics; research and development of products, namely, extracellular vesicle-based diagnostic products, extracellular vesicle-based therapeutic products; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; laboratory research services relating to research in the field of extracellular vesicle-based diagnostics and extracellular vesicle-based therapeutics; scientific laboratory research and analysis services; scientific laboratory research and analysis services for research and analysis of new products in the field of cell therapeutics; scientific laboratory research and analysis services for research and analysis of new products, namely, extracellular vesicle-based diagnostic products, extracellular vesicle-based therapeutic products; analysis of tissues for medical research; research and development services in the field of antibody generation; molecular target discovery and development services; recombinant human protein production cell line, namely, culturing of cells for others for scientific research purposes

Pharmaceutical, biotechnology and medical preparations and substances for the prevention, diagnosis or treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases; pharmaceutical, biotechnology and medical preparations and substances for the treatment, reconstruction and repair of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases using antibodies or exosomes; diagnostic preparations and reagents for medical purposes; diagnostic preparations for medical laboratory use and reagents for medical diagnostic use, namely, extracellular vesicles, RNA, protein arrays or monoclonal antibodies; monoclonal antibodies for medical purposes; monoclonal antibody fragments for medical purposes; monoclonal antibody conjugates for medical purposes; preparations for the treatment, reconstruction and repair of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases using antibodies; immunological antibodies for medical use; monoclonal antibodies for diagnostic medical use; monoclonal antibodies for medical use; monoclonal antibodies for therapeutic purposes; products containing antibodies for use in medicine, namely, extracellular vesicles, RNA, protein arrays or monoclonal antibodies; proteins for medical use in binding antibodies; proteins for medical use in detecting antibodies; reagents for use in the development of monoclonal antibodies for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancer viral or bacterial infection; vaccines for human use; vaccine adjuvants; diagnostic preparations, reagents, pharmaceutical and biochemical anti-cancer substances, products for the prevention, diagnosis or treatment of cancer, neurodegenerative, inflammatory, and metabolic diseases, and testing materials, namely, diagnostic test strips, immunoassays, PCR or genetic tests for in-vitro diagnostic use for medical purposes; diagnostic preparations and reagents for medical purposes, namely, diagnostic biomarker reagents; reagents for use in diagnostic tests for medical purposes; reagents for medical diagnosis; proteins for use in recombinant DNA technology for medical diagnosis purposes; proteins, namely protein arrays for use in recombinant DNA technology for medical diagnosis purposes; biological reagents for use in molecular biology for medical purposes

Biotechnology medical apparatus for the prevention, diagnosis or treatment of cancer, neurodegenerative, inflammatory, and metabolic diseases; biotechnology medical apparatus, namely, medical apparatus for the capture of extracellular vesicles; medical diagnostic apparatus and instruments for testing biofluids, plasma, serum, saliva, urine and cell cultures for sale in kit form

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 6, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
May 19, 2025 FICS
FINAL DISPOSITION PROCESSED
May 19, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 17, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 17, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 17, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 15, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 15, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 25, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 11, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 11, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 11, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 11, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 11, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 7, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 7, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 7, 2024 TROA
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 11, 2024 OPNX
REFUSAL PROCESSED BY IB
Feb 26, 2024 RFNT
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 21, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 21, 2024 OPNR
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 7, 2024 RFCS
REFUSAL PROCESSED BY MPU
Feb 7, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 22, 2023 RFCR
NON-FINAL ACTION WRITTEN
Mar 21, 2023 CNRT
ASSIGNED TO EXAMINER
Mar 10, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 24, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 20, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 16, 2022 REPR